Cancer Current Trials

Celldex has four clinical programs currently under clinical evaluation for the therapy of cancer.

  • CDX-110 - Clinical Program for Malignant Glioblastoma (GBM)
    Our lead clinical development program, CDX-110, is an immunotherapy that targets the tumor specific molecule called EGFRvIII, a functional variant of the epidermal growth factor receptor (EGFR), a protein that has been well validated as a target for cancer therapy. While many different epithelial tumors express this antigen, GBM has a particularly dire prognosis and is our primary indication at this time. Additional tumors will be evaluated in collaboration with Pfizer, our partner on this program.
  • CDX-011 - Clinical Program for Locally Advanced or Metastatic Breast Cancer and Unresectable Stage III or Stage IV Melanoma
    Our lead antibody-drug conjugate (ADC), CDX-011, is in Phase 2 development for the treatment of locally advanced or metastatic breast cancer and stage III or IV melanoma. CDX-011 targets glycoprotein NMB, also known as osteoactivin, a protein overexpressed on the surface of cancer cells in these and other types of cancers. Phase 2 studies are evaluating the activity and safety of CDX-011 in locally advanced or metastatic breast cancer and unresectable stage III or IV melanoma.
  • CDX-1307 - Clinical Program in hCG-Beta expressing malignancies
    Our lead APC Targeting Technology™ product candidate, CDX-1307, targets the beta chain of human chorionic gonadotropin, known as hCG-β, an antigen often found in these and other types of tumors. CDX-1307 has been evaluated for the treatment of advanced colorectal, pancreatic, bladder, ovarian and breast cancers in two Phase 1 trials. The Phase 1 data provide the basis for advancing CDX-1307 into a front-line patient population selected for hCG-β expressing cancers. A Phase 2 trial of CDX-1307 in the treatment of newly diagnosed bladder cancer is underway.
  • CDX-1401 - Clinical Program in NY-ESO-1 expressing malignancies
    Our second APC Targeting Technology™ product candidate, CDX-1401, is in Phase 1/2 development for the treatment of cancers known to express NY-ESO-1, including cancers of the bladder, breast, ovary, non-small cell lung cancer, myeloma, sarcoma and melanoma. This product is intended to selectively deliver the NY-ESO-1 antigen to Antigen-Presenting Cells (APCs) for generating robust immune responses against cancer cells expressing NY-ESO-1.

Print Page